ArticleBiochemistry and biophysics reports2025
Promotional effects of aged ZnO nanoparticles on migration, invasion and metastasis of human breast cancer MCF-7 cells
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The high success of ZnO nanoparticles (NPs), mainly associated with their unique physicochemical properties, biocompatibility, and cost-effective mass production, has led to an increasing application in our daily life, industry and biomedical fields. Although many studies have been carried out to detect potential toxicity of pristine ZnO NPs, most of them have been developed under acute and short-term exposure conditions. In terms of human risk, the evaluation of long-term exposures to sub-toxic doses of NPs, especially regarding environmental transformed (aged) ZnO NPs remains a challenge. Our previous findings have revealed that ZnO NPs underwent physicochemical transformations with aging and its genotoxicity/carcinogenicity change accordingly. Methods: In the present work, we focused on to determine the cancer progression-related end-points under a scenario of four months exposure to non-cytotoxic aged ZnO NPs (1.5 μg/mL) in MCF-7 cells (a human breast cancer cell line with poor tumorigenicity in nude mice). We performed the Results: The results showed that aged ZnO NPs significantly enhanced the migration and invasion ability of MCF-7 cells Conclusion: The study points out the potential cancer-promoting risks of exposure to ZnO NPs at low dose and under long-term exposure condition, and the importance of using real-life exposure scenarios to fully assess the safety of NPs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.